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Benefit vs potential harm of genome-wide prenatal
cfDNA testing requires further investigation and
should not be dismissed based on current data
The field of prenatal screening has rapidly changed as
a result of the introduction of cell-free DNA (cfDNA)
testing1,2. cfDNA testing can be offered as targeted ana-
lysis for the three common trisomies or as genome-wide
(GW) analysis. GW-cfDNA testing may reveal findings
other than trisomies 13, 18 and 21, such as rare autosomal
trisomies (RATs) and structural aberrations (SA).
In an Opinion paper published in this Journal, Jani
et al. argue that healthcare providers and grant-awarding
bodies should hold back on supporting research for
GW-cfDNA screening3. They raise several concerns
regarding GW-cfDNA testing and suggest that an
implementation study investigating the additional value
of GW over targeted cfDNA testing, such as the Dutch
TRIDENT-2 study4, may be ethically questionable.
We disagree with holding back on research and, in
fact, we argue that research on the clinical benefits and
potential harms of GW-cfDNA testing is important to
support responsible implementation, and that it can be
considered unethical to restrain from it. As scientific data
regarding GW-cfDNA testing in an unselected population
are currently lacking, further research is essential.
The Netherlands is one of the first countries to perform
a nationwide implementation study (TRIDENT-2 study)
of GW-cfDNA as a first-tier test offered to all pregnant
women4. Jani et al.3 refer to that study but omit
to mention that participants can choose to undergo
targeted or GW testing, with the large majority of
women (78%) preferring GW-cfDNA testing4. The fact
that the TRIDENT-2 study is a government-controlled
implementation study offers the unique opportunity to
analyze a large dataset with well-documented numbers
on uptake, test performance and invasive follow-up
procedures, but also assess the quality of protocolized
pre- and post-test counseling and obtain insights into the
perspectives of the pregnant women, such as parental
anxiety. All study outcomes together will allow the
Dutch healthcare policy makers to reach a decision about
implementation of cfDNA testing (targeted or GW) as a
first-tier screening test in clinical practice, supported by
evidence-based research.
Of concern are several misinterpretations by Jani et al.
concerning the TRIDENT-2 study data, especially when
it comes to over-interpretation of clinical findings. It is
stated clearly in the TRIDENT-2 publication that the
reported data are preliminary results and that complete
clinical outcome data still need to be analyzed4. Jani et al.
incorrectly state that only one of the six fetuses with a
confirmed RAT had an abnormal phenotype, which is
not known yet. Furthermore, they argue that the 29 cases
with confirmed fetal SAs could have been discovered by
ultrasound. Again, this outcome is not known yet, but
their assumption is very unlikely to be true as not all
clinically significant additional findings of GW-cfDNA
testing (RATs, SAs) are associated with structural
ultrasound anomalies5. Indeed, not all fetal anomalies can
be detected by prenatal ultrasound, especially not at an
equally early gestational age. A previous study has shown
that 38.6% of the cases with additional findings detected
via cfDNA testing in a cohort of 15 626 consecutive
pregnancies had no ultrasound anomalies6. Lastly, Jani
et al. suggest that, in seven cases consistent with maternal
(pre)malignancy, the benefit of the discovery was not
demonstrated. Again, this statement is premature. We
found five cases of hematological malignancy, one of
breast carcinoma and one case of a premalignant breast
ductal carcinoma in situ4. These are medical conditions
that are likely to require rapid treatment and can therefore
be considered relevant, as shown in previous studies7.
Abnormal cfDNA-screening results necessitate invasive
follow-up testing. Jani et al. raise the concern that
GW-cfDNA testing may lead to a substantial increase in
the rate of invasive tests due to discordant positive test
results, when the introduction of non-invasive cfDNA
testing aimed to reduce this. Although the majority of
the RATs and SAs reported in the TRIDENT-2 study
could not be confirmed in the fetus after invasive testing,
it is important to realize that the overall prevalence
of additional findings in a general population is low
(0.36%)4. Therefore, the overall number of invasive
tests in The Netherlands since the introduction of
GW-cfDNA testing is much lower as compared to that in
the era before the TRIDENT studies, when first-trimester
combined testing was the sole screening test offered4,5.
The results of the TRIDENT-1 study, offering
GW-cfDNA testing to high-risk women8, and of other
studies9 have shown that the risk of an adverse pregnancy
outcome is increased by 23–45% due to fetal growth
restriction (FGR), structural anomalies or intrauterine
fetal demise, even if the additional finding is confined to
the placenta (confined placental mosaicism (CPM)). Also,
CPM may be a marker for uniparental disomy (UPD)
which can have clinical consequences depending on the
chromosome involved.
Jani et al.3 argue that the incidence of adverse preg-
nancy outcome is not increased in cases with CPM, except
when it involves trisomy 16. This assumption is based
on the findings from one study in which CPMs were
identified in chorionic villus samples in an unselected
population10, that, in our view, cannot be extrapolated
to the CPM cases identified by cfDNA testing11. It is
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hypothesized that, in cases with CPM, the presence of
a trisomy in the placenta alters its function. Pregnancies
with CPM have a risk of developing FGR compared
to those without CPM, and this is not observed only
for trisomy 1612. The ratio of placental infarcts nearly
doubled in cases with CPM compared to chromosomally
normal placentas from FGR fetuses12.
Finally, Jani et al.3 raise concerns regarding parental
counseling and termination of pregnancy after additional
findings on GW-cfDNA testing. We agree that both pre-
and post-test counseling is important. In the TRIDENT-2
study4, cfDNA testing can only be offered and counseled
by counselors, who inform prospective parents about the
possibility of uncertain results, such as fetal mosaicism,
CPM but also maternal disease. Post-test counseling
in cases of findings other than trisomy 21, 18 or 13
is carried out only by clinical geneticists. At post-test
counseling, patients are informed about the test result,
they are offered follow-up diagnostic testing to assess
the clinical significance of the finding and it is clarified
that termination of pregnancy cannot be offered before
such testing has been performed. Assessment of patient
perspectives, including psychological harm as well as the
quality of counseling and decision-making, are important
outcomes of the TRIDENT-2 study4.
In conclusion, the clinical consequences of additional
findings by GW-cfDNA testing require further research
and the benefits need to be critically balanced against
potential harms. Healthcare policymakers worldwide
should encourage research that thoroughly and critically
assesses all aspects of GW-cfDNA testing. The Dutch
TRIDENT studies are good examples of such research,
and preliminary data from these studies should not be
used to draw far-fetched conclusions.
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